From version < 4.1
edited by Asif Farooqui
on 2021/04/06 15:28
To version < 3.1 >
edited by Asif Farooqui
on 2021/04/06 15:27
<
Change comment: Uploaded new attachment "SUNPHARMA.jpg", version {1}

Summary

Details

Page properties
Content
... ... @@ -12,10 +12,6 @@
12 12  
13 13  Sun Pharma has 44 manufacturing sites approved by global health regulatory agencies—supported by a worldwide supply chain—and multiple research and development (R&D) facilities across the world, investing 6.9% of its sales in R&D. It has a diverse employee base of 32,000+ individuals across 50 nationalities worldwide.
14 14  
15 -
16 -[[image:SUNPHARMA.jpg]]
17 -
18 -
19 19  = Business Overview =
20 20  
21 21  == Research & Development ==
... ... @@ -185,19 +185,6 @@
185 185  
186 186  Sun Pharmaceutical has a comprehensive product offering in the US market consisting of approved ANDAs for 483 products while filings for 98 ANDAs await US FDA approval, including 20 tentative approvals. For the quarter, 6 ANDAs were filed and 2 approvals were received. Additionally, the pipeline includes 55 approved NDAs await US FDA approval.
187 187  
188 -
189 -= Recent developments =
190 -
191 -**Sun Pharma Consolidated December 2020 Net Sales at Rs 8,836.78 crore, up 8.36% Y-o-Y **{{footnote}}https://www.moneycontrol.com/news/business/earnings/sun-pharma-consolidated-december-2020-net-sales-at-rs-8836-78-crore-up-8-36-y-o-y-6432631.html{{/footnote}}
192 -
193 -**February 02, 2021**; Reported Consolidated quarterly numbers for Sun Pharmaceutical Industries are:
194 -
195 -* Net Sales at Rs 8,836.78 crore in December 2020 up 8.36% from Rs. 8,154.85 crore in December 2019.
196 -* Quarterly Net Profit at Rs. 1,913.41 crore in December 2020 up 87.7% from Rs. 1,019.38 crore in December 2019.
197 -* EBITDA stands at Rs. 2,721.09 crore in December 2020 up 38.74% from Rs. 1,961.28 crore in December 2019.
198 -* Sun Pharma EPS has increased to Rs. 7.72 in December 2020 from Rs. 3.81 in December 2019.
199 -
200 -
201 201  = References =
202 202  
203 203  {{putFootnotes/}}
This site is funded and maintained by Fintel.io